VITRECTO Solution

Pays: Canada

Langue: français

Source: Health Canada

Ingrédients actifs:

FLURALANER; Moxidectine

Disponible depuis:

INTERVET CANADA CORP

Dosage:

112.5MG; 5.6MG

forme pharmaceutique:

Solution

Composition:

FLURALANER 112.5MG; Moxidectine 5.6MG

Mode d'administration:

Topique

Unités en paquet:

15G/50G

Type d'ordonnance:

Prescription

Groupe thérapeutique:

Chats

Descriptif du produit:

Numéro de groupe d'ingrédients actifs (GIA) :0261730001

Statut de autorisation:

APPROUVÉ

Date de l'autorisation:

2019-08-23

Notice patient

VITRECTO
Fluralaner and Moxidectin Topical Solution
PACKAGE INSERT
Version 05MAY2023
1
Confidential
DIN 02491729, 02491737, 02491745
Pr
ViTRECTO
®
Fluralaner and Moxidectin Topical Solution
Veterinary Use Only
DESCRIPTION:
VITRECTO (Fluralaner and Moxidectin Topical Solution) contains 280
mg/mL (28% w/v) of
fluralaner and 14 mg/mL (1.4% w/v) of moxidectin. Each single use tube
is formulated to provide
a minimum dose of 40 mg/kg body weight of fluralaner and 2 mg/kg of
moxidectin.
Non-Medicinal
Ingredients:
Butylhydroxytoluene,
Dimethylacetamide
(DMA),
Glycofurol,
Diethyltoluamide (DEET), Acetone.
THERAPEUTIC CLASSIFICATION:
Antiparasitic
INDICATIONS
:
VITRECTO is indicated for cats and kittens 6 months of age and older
and weighing 1.2 kg or
greater.
VITRECTO is indicated every 2 months for:
-
The treatment and prevention of flea infestations (
_Ctenocephalides felis_
)
-
The treatment and control of tick infestations with
_Ixodes scapularis _
(black-legged tick)
-
The prevention of heartworm disease caused by
_Dirofilaria immitis_
VITRECTO is effective for the treatment and control of tick
infestations with
_Haemaphysalis _
_longicornis_
(Asian longhorned tick) for 12 weeks.
VITRECTO is also indicated for the treatment of infections with
intestinal roundworm (
_Toxocara _
_cati_
; 4
th
stage larvae, immature adults and adults) and hookworm (
_Ancylostoma tubaeforme_
; 4
th
stage larvae, immature adults and adults).
DOSAGE AND ADMINISTRATION
:
VITRECTO should be administered topically as a single dose every 2
months according to the
DOSAGE SCHEDULE
below to provide a minimum dose of 40 mg fluralaner and 2 mg
moxidectin per
kg body weight. It is important to exactly follow a bi-monthly
administration to ensure optimum
prevention of heartworm disease in cats.
For prevention of heartworm disease, VITRECTO administration should
begin one month after
the first expected exposure to mosquitoes and continue at 2-month
intervals until last exposure to
mosquitoes.
VITRECTO
Fluralaner and Moxidectin Topical Solution
PACKAG